AgeX Therapeutics, Inc. announced that on November 22, 2022 it received notification from the staff of the NYSE American that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003 and of the Exchange Company Guide by increasing its stockholders equity to not less than $4,000,000.
November 25, 2022
· 3 min read